Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Icotinib Hydrochloride (BPI-2009H) is the hydrochloride salt form of icotinib, an orally available quinazoline-based inhibitor of EGFR, with potential antineoplastic activity. Icotinib selectively inhibits the wild-type and several mutated forms of EGFR tyrosine kinase. This may lead to an inhibition of EGFR-mediated signal transduction and may inhibit cancer cell proliferation. EGFR, a receptor tyrosine kinase, has been upregulated in a variety of cancer cell types.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
5 mg | 在庫あり | ¥ 13,000 | |||
10 mg | 在庫あり | ¥ 18,500 | |||
25 mg | 在庫あり | ¥ 33,000 | |||
50 mg | 在庫あり | ¥ 55,000 | |||
100 mg | 在庫あり | ¥ 81,500 | |||
200 mg | 在庫あり | ¥ 121,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 14,000 |
説明 | Icotinib Hydrochloride (BPI-2009H) is the hydrochloride salt form of icotinib, an orally available quinazoline-based inhibitor of EGFR, with potential antineoplastic activity. Icotinib selectively inhibits the wild-type and several mutated forms of EGFR tyrosine kinase. This may lead to an inhibition of EGFR-mediated signal transduction and may inhibit cancer cell proliferation. EGFR, a receptor tyrosine kinase, has been upregulated in a variety of cancer cell types. |
ターゲット&IC50 | EGFR:5 nM |
別名 | BPI-2009H |
分子量 | 427.88 |
分子式 | C22H22ClN3O4 |
CAS No. | 1204313-51-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 12 mg/mL (28.04 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Icotinib Hydrochloride 1204313-51-8 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR Epidermal growth factor receptor HER1 Inhibitor BPI-2009H ErbB-1 Icotinib inhibit inhibitor